Abstract |
Epidermal growth factor receptor (EGFR) is one of the most promising targets for non-small cell lung cancer (NSCLC). Our study demonstrated the antitumor effects of icotinib hydrochloride, a highly selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), in two EGFR-mutated lung cancer cell lines compared to A549, a cell line without EGFR mutations. We incubated PC-9 and HCC827 human lung cancer cell lines both with (E746-A750) mutations with various concentrations of icotinib and gefitinib for 48 h. Cell proliferation and migration were determined using a real-time cell invasion and migration assay and cytotoxicity assay. Apoptosis was assessed by measuring Annexin V staining using flow cytometry. The antitumor effects of icotinib compared to gefitinib were similar and were most effective in reducing the proliferation of EGFR-mutated cells compared to non-mutated controls. Our results suggest the possibility of icotinib as a new therapeutic agent of EGFR-mutated cancer cells, which has the potential to be used in the first-line treatment of EGFR-mutated NSCLC.
|
Authors | Guangdie Yang, Yinan Yao, Jianya Zhou, Qiong Zhao |
Journal | Oncology reports
(Oncol Rep)
Vol. 27
Issue 6
Pg. 2066-72
(Jun 2012)
ISSN: 1791-2431 [Electronic] Greece |
PMID | 22446631
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Crown Ethers
- Quinazolines
- icotinib
- ErbB Receptors
- Gefitinib
|
Topics |
- Antineoplastic Agents
(pharmacology)
- Apoptosis
(drug effects)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, genetics)
- Cell Line, Tumor
- Cell Movement
(drug effects)
- Cell Proliferation
(drug effects)
- Crown Ethers
(pharmacology)
- ErbB Receptors
(antagonists & inhibitors, genetics)
- Gefitinib
- Humans
- Lung Neoplasms
(drug therapy, genetics)
- Mutation
- Quinazolines
(pharmacology)
|